Protagonist Therapeutics, Inc Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Protagonist Therapeutics, Inc (PTGX) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of $4.78 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-02-25
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was $4.78M, a 76.95% increase from fiscal 2024.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was $2.70M, a 22.35% increase from fiscal 2023.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $2.21M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-12-31 | $4.78M 10-K · filed 2026-02-25 |
| 2024-12-31 | $2.70M 10-K · filed 2026-02-25 |
| 2023-12-31 | $2.21M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |